Barclays Says MedTech Stocks Are at Their Cheapest in a Decade — and Names 2 Stocks to Buy
Barclays analyst Christopher Pasquale identifies Stryker (SYK) and Beta Bionics (BBNX) as attractive investment opportunities in the MedTech sector. SYK reported 2Q26 revenue of $6.6B, up 9.4% YoY, with an Overweight rating and $375 price target. BBNX reported 2Q26 revenue of $32M, up 38% YoY, with a positive outlook on market share growth.
How this was made
The 30-second read
Why it matters
The note provides fresh analyst ratings and price targets, creating immediate trading catalysts for the two companies.
Market read
The recommendations could drive short-term buying pressure in Stryker and Beta Bionics, and signal broader MedTech sector strength.
What to watch
Potential regulatory scrutiny on medical devices and the competitive landscape could temper upside.
Background
Barclays analyst Christopher Pasquale publishes a note recommending two MedTech stocks as the cheapest in a decade.
Ticker impact
Barclays analyst upgrades Stryker to Overweight with a $375 price target, citing recovery from cyberattack and growth outlook.
upward pressure as investors price in the new target and rating.
The upgrade is a fresh primary recommendation with a specific upside target, providing a clear catalyst.
Barclays analyst rates Beta Bionics Overweight with a bullish outlook and expects revenue growth and margin expansion.
potential upside as the market absorbs the new rating and growth forecasts.
First report of an analyst upgrade with explicit growth thesis offers a tangible trading signal.
Market effects
Both upgrades highlight renewed optimism in the MedTech sector, potentially lifting peers.
U.S. healthcare stocks may see modest gains as analysts spotlight growth opportunities.
Limited to investors focused on U.S. medical device and biotech equities.
Counterpoint
Some investors may remain cautious given Stryker's recent cyberattack and Beta Bionics' ongoing losses.
Key entities
- Financial InstitutionBarclays
Issuer of the analyst research note.
- AnalystChristopher Pasquale
Barclays analyst authoring the recommendation.
